<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Wed, 10 Jun 2026 16:37:54 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] 老化細胞を若返らせる遺伝子治療が試験で最初の患者に与えられた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110038&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110038&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / その他臨床試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 16:37:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110038&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 幼くしての死亡率の低下が2015年以降より遅くなっている</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110037&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110037&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 15:23:19 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110037&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 転帰の鞍替えをした観察試験の殆どがとどのつまり体良く有意結果になっていた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110036&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110036&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 14:55:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110036&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 健康体の人にラッサウイルス（LASV）ワクチンを接種したPh1試験が好成績</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110035&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110035&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 13:17:33 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110035&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 結核ワクチンBCGが子供の頃から1型糖尿病（T1D）の成人に有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110034&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110034&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 11:28:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110034&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Parabilis社が予定のIPO調達を最大6億ドル超に引き上げた</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110033&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110033&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / IPO</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 10:19:49 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110033&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Bial社のパーキンソン病薬BIA 28-6156のPh2試験失敗〜その用途の開発中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110032&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110032&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止 || 開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 08:54:31 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110032&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] FDA承認審査段階の肺癌薬2つを擁するNuvalent社をGSKが106億ドルで買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110031&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110031&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 08:06:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110031&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AlzeCure社のAβ42生成阻害薬ACD680をLillyが手に入れる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110030&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110030&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 10 Jun 2026 07:09:42 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110030&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] BI社のsurvodutideでMASH患者肝脂肪59%減少〜胃腸の害で5人に1人が投与中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110029&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110029&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 16:39:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110029&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] GSKがEngitixと組んで肝線維症解消と関連する治療標的を見つける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110028&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110028&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 16:07:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110028&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] GileadとMerck &amp; Coの手持ちを組み合わせたHIV薬週1回1錠服用Ph3試験2つ成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110027&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110027&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 15:46:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110027&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 先立つ治療がまだの肺癌のGilead社のTrodelvy込み治療の無増悪生存改善示せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110026&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110026&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 15:10:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110026&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 肥えた成人の32週時点体重がPfizerのGLP-1薬berobenatide週1回投与で16%減</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110025&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110025&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 14:40:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110025&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 糖のユビキチン化を発見〜肝臓の貯蔵された糖の分解の一端を担うらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110024&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110024&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 13:49:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110024&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 癌を治療する蛋白質分解薬付き抗体のFirefly社をJ&amp;Jが大枚10億ドルで買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110023&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110023&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 12:39:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110023&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Incyte社がStar社の子会社を買ってPh3試験段階のフォンビレブランド病薬を得る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110022&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110022&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 11:55:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110022&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 間もなく白血病Ph3試験が始まるNurix社のBTK分解薬の世話にRocheが加わる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110021&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110021&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 11:20:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110021&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] BI社のグルカゴン/GLP1両取り薬survodutideを4人に1人もが有害事象で取りやめ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110020&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110020&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 10:52:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110020&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] AstraZenecaの経口GLP-1薬elecoglipronのPh2試験2つの論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110019&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110019&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 10:02:58 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110019&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの経口GLP1薬orforglipronがFarxigaに勝った糖尿病Ph3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110018&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110018&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 09:32:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110018&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Novo社のCagriSemaの2型糖尿病治療の取り柄を示したPh3試験一揃い論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110017&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110017&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 09 Jun 2026 06:55:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110017&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Lillyの3G薬retatrutideが2型糖尿病患者体重を多ければ15%減らしたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110016&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110016&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 16:48:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110016&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Bayerの慢性腎疾患薬Kerendiaが無作為化試験3つまとめ解析で死亡さえ減らした</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110015&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110015&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 16:21:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110015&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Novartisの取り急ぎ承認IgA腎症薬が肝心要のeGFR目標を逃したPh3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110014&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110014&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 15:54:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110014&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ワクチン接種サルから見つかった抗体がマウスのエンテロウイルスD68感染予防</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110013&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110013&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 14:47:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110013&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] HIV感染T細胞のCD4+からCD8+への転身を発見〜CD8+T細胞にもHIVが潜みうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110012&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110012&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 12:39:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110012&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] TDP-43を介したmRNAスプライシングを受ける神経興奮従事遺伝子一揃いを発見</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110011&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110011&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 12:19:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110011&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ホスファチジルセリンを表面に密に纏った血小板で速やかな止血を促しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110010&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110010&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 11:39:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110010&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 【増補版】拒食症患者の7割ほどに脂肪中心のケトン食が有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110009&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110009&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 08 Jun 2026 10:51:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110009&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 神経性無食欲（拒食症）患者の7割ほどが脂肪中心のケトン食で回復</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110008&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110008&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 16:33:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110008&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 肺の微生物組成の乱れを減らすTLR5活性化が特発性肺線維症の治療法となりうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110007&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110007&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 09:57:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110007&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] クローディン1（CLDN1）阻害で胆管癌増殖阻止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110006&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110006&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 07:58:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110006&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] SanofiがOwkinのAI科学者K Proを手足とする自ずと働くAIを開発して導入する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110005&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110005&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 07 Jun 2026 07:19:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110005&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Rocheの抗CD20抗体obinutuzumabで原発性膜性腎症患者の4割弱37%が完全寛解</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110004&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110004&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 16:51:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110004&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 非糖尿病患者腎機能値eGFR年換算低下をBayerのKerendiaがプラセボ差引0.7抑制</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110003&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110003&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 13:55:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110003&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Pfizerが中国Chai Discovery社の人工知能（AI）利用創薬に取り組む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110002&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110002&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 12:08:49 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110002&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Zenas社のCD19-FcγRIIb両取り抗体がIgG4病フレアを56%減らしたPh3試験論文</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110001&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110001&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 11:20:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110001&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] リウマチ性多発筋痛症再発患者の4割ほどがNovartisのCosentyxで持続寛解</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110000&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110000&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 06 Jun 2026 10:22:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110000&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 大塚製薬のAPRIL阻害抗体VoyxactがPh3試験でIgA腎症患者の腎機能維持</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109999&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109999&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 05 Jun 2026 07:29:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109999&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 武田薬品が中国外権利を有する抗CLDN18.2 ADCが胃癌Ph3試験PFS目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109998&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109998&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 05 Jun 2026 06:53:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109998&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 急性骨髄性白血病と診断されたばかりの75歳以上の患者の経口薬のみ治療が有益</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109997&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109997&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 20:56:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109997&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] J&amp;JのFcRn遮断薬nipocalimabのSLE奏効率がプラセボを差し引きで7%上回った</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109996&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109996&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 12:08:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109996&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 腫瘍に至って活性化する二重特異性抗体を作るRegeneron社とCytomXの提携拡大</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109995&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109995&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 11:28:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109995&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Alnylam社がInceptive Nucleics社のAI技術を利用したRNA干渉薬作りに取り組む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109994&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109994&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 10:51:21 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109994&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 来年Ph3試験が始まる男性避妊薬の開発資金1億ドル弱をContraline社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109993&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109993&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 10:27:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109993&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] RNA書き換えによる治療を開発しているAscidian社とLillyが提携</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109992&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109992&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 09:28:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109992&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Modernaのブンディブギョ株エボラワクチン開発にCEPIが多ければ5千万ドル提供</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109991&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109991&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 08:47:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109991&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Legend社の体内で作るCAR-Tで再発/治療抵抗性非ホジキンリンパ腫患者全員奏効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109990&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109990&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 04 Jun 2026 07:19:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109990&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] GSKのKIT阻害薬velzatinibの消化管間質腫瘍初治療の暫定奏効率61%（11/18人）</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109989&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109989&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 03 Jun 2026 17:01:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109989&amp;ref=rss</comments>
	</item>
</channel>
</rss>
